Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.34), $0.20 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $5.67 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.